Literature DB >> 12574174

Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?

Matthew C Riddle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12574174     DOI： 10.1210/jc.2002-021971

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  23 in total

1.  Bovine herpesvirus 1 productive infection stimulates inflammasome formation and caspase 1 activity.

Authors:  Jianlin Wang; Jeff Alexander; Matthew Wiebe; Clinton Jones
Journal:  Virus Res       Date:  2014-03-20       Impact factor: 3.303

Review 2.  Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes.

Authors:  Mary Elizabeth Cox; Mark N Feinglos
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

3.  The antidiabetic agent glibenclamide protects airway hyperresponsiveness and inflammation in mice.

Authors:  Wei Cui; Shufang Zhang; Zhijian Cai; Xinlei Hu; Ruifeng Zhang; Yong Wang; Na Li; Zhihua Chen; Gensheng Zhang
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

4.  Anti-nociceptive and anti-edematogenic effects of glibenclamide in a model of acute gouty attack in rats.

Authors:  Rosane M S dos Santos; Sara M Oliveira; Cássia R Silva; Carin Hoffmeister; Juliano Ferreira; Jamil Assreuy
Journal:  Inflamm Res       Date:  2013-03-30       Impact factor: 4.575

Review 5.  Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?

Authors:  George Grunberger
Journal:  Curr Diab Rep       Date:  2017-04       Impact factor: 4.810

Review 6.  Are sulfonylureas passé?

Authors:  Jennifer B Green; Mark N Feinglos
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

7.  Thiazolidinediones and cardiovascular risk - a question of balance.

Authors:  Erland Erdmann; Bernard Charbonnel; Robert Wilcox
Journal:  Curr Cardiol Rev       Date:  2009-08

Review 8.  GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects.

Authors:  Melanie Sulistio; Curtis Carothers; Mandeep Mangat; Mike Lujan; Rene Oliveros; Robert Chilton
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

9.  The Pathogenic Role of NLRP3 Inflammasome Activation in Inflammatory Bowel Diseases of Both Mice and Humans.

Authors:  Ling Liu; Ying Dong; Mei Ye; Shi Jin; Jianbo Yang; Maria E Joosse; Yu Sun; Jennifer Zhang; Mark Lazarev; Steven R Brant; Bashar Safar; Michael Marohn; Esteban Mezey; Xuhang Li
Journal:  J Crohns Colitis       Date:  2017-06-01       Impact factor: 9.071

10.  Glyburide inhibits the Cryopyrin/Nalp3 inflammasome.

Authors:  Mohamed Lamkanfi; James L Mueller; Alberto C Vitari; Shahram Misaghi; Anna Fedorova; Kurt Deshayes; Wyne P Lee; Hal M Hoffman; Vishva M Dixit
Journal:  J Cell Biol       Date:  2009-10-05       Impact factor: 10.539
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.